Mechanostics®

Treatment Optimization

Targeting treatments to the right patients

Mechanostics enable targeted decision-making by identifying the specific disease mechanisms active in each patient – stratifying patients by mechanism, and showing the therapy that is most likely to be effective for them.

These insights determine which patients are most likely to benefit from a given treatment – and potentially avoid adverse reactions, and tolerability issues.

This approach enables payers to prioritize the treatments that align with the patient’s underlying disease biology. For example, mechanostics tests can identify those patients most likely to benefit from GLP-1 receptor agonists.

For biopharma, CRO & diagnostics

Biopharmaceutical, CRO and diagnostics companies can develop and easily deploy our mechanostic tests as high-value companion diagnostics that support precision regulatory strategies, personalized treatment strategies and improve therapy ROI.

For payers

Healthcare payers may benefit from being able to identify patients who will not tolerate specific drugs, saving them from adverse events, lowering overall drug costs and giving better patient outcomes.

Clinical Trial Recruitment

Smarter recruitment for faster, more effective trials

Mechanostics transform trial recruitment by identifying patients with the specific genotypic and mechanistic profiles that are targeted by new investigational therapies - improving response rates and trial efficiency from the outset.

Our low-cost, non-invasive tests use saliva or buccal swabs and run on standard genotyping arrays compatible with CLIA/CAP-accredited labs worldwide.

This makes Mechanostic screening highly scalable, enabling rapid pre-screening of large patient registries and populations across diverse sites and geographies.

For clinical trial design & enrichment

Biotech and pharma partners can run smaller, faster, and more successful trials by enriching for the patients most likely to respond. Mechanostics reduce response heterogeneity, improve targeting of inclusion criteria, and support enriched trial design strategies.

By combining precision recruitment with global scalability, Mechanostics can lower drug development risk, accelerate timelines, and increase the probability of success – helping to bring precision therapies to market faster.

Disease Risk Prediction

Identifying at-risk patients before symptoms emerge

Mechanostics enable proactive healthcare by detecting subtle, highly predictive genotypic signatures long before clinical symptoms arise. Using combinatorial analytics, our tests identify individuals at elevated risk based on the specific biological mechanisms that drive disease.

The tests make large-scale population screening practical and cost-effective with low-cost test kits and compatibility with widely available genotyping arrays.

For diagnostics

Diagnostics providers can offer next-generation risk prediction tools in complex diseases affecting hundreds of millions of patients. Adding clinical value and creating new revenue streams.

For healthcare

Healthcare providers benefit from earlier interventions, reduced late-stage diagnoses, and the ability to shift from reactive treatment to preventative care – improving outcomes while lowering long-term costs.

Early Intervention & Prevention

Detecting risk and preventing disease with clinically actionable insights

Mechanostics determine an individual's lifetime risk of developing specific chronic diseases by identifying the genotypic signatures and biological mechanisms that drive (and prevent) disease onset.

This empowers clinicians to implement tailored early interventions - from lifestyle modifications and active monitoring to prophylactic therapies - to delay or even prevent disease progression.

PrecisionLife is uniquely positioned to go further, identifying actively protective biology (disease resilience mechanisms) that informs the development of next-generation prophylactic drugs and vaccines targeting major chronic conditions.

For diagnostics 

Diagnostics providers can expand the value of routine testing into common chronic diseases by offering predictive tools that support prevention-focused care models and public health strategies.

For healthcare

Healthcare systems benefit from a measurable reduction in future disease burden, enabling more sustainable care delivery and longer, healthier lives for patients.